[HTML][HTML] Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine
…, N Formica, V Shinde, L Fries, JD Lickliter… - New england journal …, 2020 - Mass Medical Soc
Background NVX-CoV2373 is a recombinant severe acute respiratory syndrome coronavirus
2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike …
2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike …
[PDF][PDF] EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme
…, G Osborne, KK Khanna, BA Reynolds, JD Lickliter… - Cancer cell, 2013 - cell.com
Significant endeavor has been applied to identify functional therapeutic targets in glioblastoma
(GBM) to halt the growth of this aggressive cancer. We show that the receptor tyrosine …
(GBM) to halt the growth of this aggressive cancer. We show that the receptor tyrosine …
First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma
JR Whittle, JD Lickliter, HK Gan, AM Scott… - Journal of Clinical …, 2015 - Elsevier
There are limited treatment options for patients with recurrent glioblastoma (GBM). The
EnGeneIC delivery vehicle (EDV) is a novel nanocellular (minicell) compound which packages …
EnGeneIC delivery vehicle (EDV) is a novel nanocellular (minicell) compound which packages …
[HTML][HTML] A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease
M Grundman, R Morgan, JD Lickliter… - Alzheimer's & Dementia …, 2019 - Elsevier
Background Elayta (CT1812) is a novel allosteric antagonist of the sigma-2 receptor
complex that prevents and displaces binding of Aβ oligomers to neurons. By stopping a key …
complex that prevents and displaces binding of Aβ oligomers to neurons. By stopping a key …
[HTML][HTML] A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours
…, E Hammond, JD Lickliter, L Lin, D Bampton… - British Journal of …, 2018 - nature.com
Background PG545 (pixatimod) is a novel immunomodulatory agent, which has been
demonstrated to stimulate innate immune responses against tumours in preclinical cancer models. …
demonstrated to stimulate innate immune responses against tumours in preclinical cancer models. …
Hepatic-targeted RNA interference provides robust and persistent knockdown of alpha-1 antitrypsin levels in ZZ patients
Background & Aims Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder causing
pulmonary and liver disease. The PiZ mutation in AAT (SERPINA1) results in mis-folded AAT …
pulmonary and liver disease. The PiZ mutation in AAT (SERPINA1) results in mis-folded AAT …
[HTML][HTML] Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical …
…, JW Wells, A Wheatley, M Pryor, JD Lickliter… - PLoS …, 2020 - journals.plos.org
Background The Vaxxas high-density microarray patch (HD-MAP) consists of a high density
of microprojections coated with vaccine for delivery into the skin. Microarray patches (MAPs) …
of microprojections coated with vaccine for delivery into the skin. Microarray patches (MAPs) …
[HTML][HTML] A controlled human infection model of Streptococcus pyogenes pharyngitis (CHIVAS-M75): an observational, dose-finding study
…, SJ Gutman, C Baker, JMF Wong, JD Lickliter… - The Lancet …, 2021 - thelancet.com
Background Streptococcus pyogenes is a leading cause of infection-related morbidity and
mortality. A reinvigorated vaccine development effort calls for new clinically relevant human S …
mortality. A reinvigorated vaccine development effort calls for new clinically relevant human S …
First-in-human phase I study of the selective MET inhibitor, savolitinib, in patients with advanced solid tumors: safety, pharmacokinetics, and antitumor activity
…, MM Frigault, S Morgan, L Yang, JD Lickliter - Clinical Cancer …, 2019 - AACR
Purpose: Aberrant activation of MET (hepatocyte growth factor receptor) signaling is implicated
in the tumorigenesis of human cancers. This phase I study assessed the safety, tolerability…
in the tumorigenesis of human cancers. This phase I study assessed the safety, tolerability…
A Cathepsin-Targeted Quenched Activity–Based Probe Facilitates Enhanced Detection of Human Tumors during Resection
…, AJM Egan, CW Bradley, E Eruslanov, JD Lickliter… - Clinical Cancer …, 2022 - AACR
Purpose: Fluorescence-guided surgery using tumor-targeted contrast agents has been
developed to improve the completeness of oncologic resections. Quenched activity–based …
developed to improve the completeness of oncologic resections. Quenched activity–based …
